Figure 1
(A) PFS and (B) OS of EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups. bev bevacizumab, TKI tyrosin kinase inhibitor.
Figure 1 | Scientific Reports
(A) PFS and (B) OS of EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups. bev bevacizumab, TKI tyrosin kinase inhibitor.
